Biotech entity
All 1 tracked stories fall under one category: pharma. AlphaFold is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 3 original sources each. John Jumper appears in 1 tracked Biotech story from June 20, 2026.
Last mentioned: Jun 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. AlphaFold is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 3 original sources each. John Jumper appears in 1 tracked Biotech story from June 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering John Jumper. Shared-story counts are live from our verified record — not editorial picks.
Nobel laureate John Jumper’s move from Google DeepMind to Anthropic casts uncertainty over the future of AlphaFold, the AI that revolutionized protein structure prediction for drug discovery. Biotech and pharma companies relying on its 200 million predicted structures now watch as Jumper’s expertise may shift to a startup facing legal battles.
Source: english.aawsat.com · cnbc.com
John Jumper is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
